Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales, general and administrative

Merger-related expenses

Change in fair value of contingent consideration

Amortization of acquired intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pacific Biosciences of California

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pacific Biosciences sees strong Revio demand driving revenue growth

PACB reported a revenue decrease in Q4 2022 but saw strong customer interest in the Revio system, driving revenue growth expectations for 2023. The company is strategically focused on Revio adoption, Onso's performance, and managing market challenges. Opportunities exist in scaling manufacturing capacity, expanding customer reach, and leveraging high demand for Revio and Onso.

PacBio surpasses revenue expectations with strong Revio demand

PacBio's Q1 2023 performance exceeded expectations with record revenue and strong Revio demand, setting up growth opportunities.
While facing challenges in gross margin and operating expenses, PacBio's innovative approach and broad market appeal position it well for the future.
With a focus on margin expansion, consumables growth, and balancing product demand, PacBio aims for sustained profitability and market leadership.
The successful Revio launch and strong China business highlight PacBio's potential for long-term growth and market impact.

PacBio reports record Q2 revenue, eyes market gains and gross margin improvements

PacBio's Q2 performance marked by record revenue, strategic acquisitions, and strong guidance update for 2023 growth.
Focus on Revio system adoption, consumables pull-through, and backlog reduction positions the company for sustained success.
Challenges include market competition, sustaining growth post-upgrade cycle, and addressing validation issues for new products.
Opportunities lie in market shifts towards long reads, improving gross margins through product mix changes, and expanding market access.

PacBio reports record Q3 revenue growth and strategic advancements

PacBio delivered robust performance in Q3, achieving record revenue and strong growth, driven by increased demand for Revio systems and consumables.
While facing challenges such as budget constraints and macroeconomic uncertainties, PacBio's strategic strengths lie in product innovation, market expansion, and financial stability.
Opportunities abound in collaborations, technology enhancements, and market growth, positioning PacBio for continued success and leadership in the genomics industry.
With a positive outlook for future revenue growth, PacBio remains focused on driving innovation, expanding its customer base, and navigating market challenges.

Pacific Biosciences reports robust 2023 performance and eyes growth

PACB had a strong 2023 with revenue growth and successful Revio adoption, despite challenges in China impacting placements.
New kits, software updates, and positive customer feedback on platforms indicate market acceptance and drive customer enthusiasm.
Strategic priorities for 2024 focus on expansion, technology development, and revenue growth, with opportunities in clinical markets and alternative business models.

Pacific Biosciences reports Q2 revenue below expectations, focuses on growth

Pacific Biosciences of California reported Q2 revenue below expectations but showed strength in consumable revenue growth. The company is focused on reducing expenses, improving cash burn, and driving instrument placements. Despite challenges, there are opportunities for growth through attractive deals and positive outlook for consumables.
The company's performance in Q2 reflects ongoing efforts to improve margins and drive revenue growth. Challenges in revenue expectations and headwinds are being addressed through cost reductions and strategic initiatives. Pacific Biosciences remains confident in its progress and future prospects.
With a focus on cost reduction, revenue improvement, and strategic priorities, Pacific Biosciences aims to achieve cash flow positivity by 2026. The company's strengths lie in consumable revenue growth, successful marketing events, and confidence in its product pipeline. Challenges in revenue and cash flow are being managed with opportunities for growth through instrument placements and deals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

PacBio (PACB) sees strength in Q1 segmental revenues, led by robust consumable and instrument sales.

PacBio's (PACB) Q1 Earnings Miss Estimates, Revenues Beat

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q1 2022 Earnings Conference Call May 4, 2022 5:00 PM ET Company Participants Todd Friedman - Director, IR Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Dan Brennan - Cowan David Westenberg - Piper Sandler Tejas Savant - Morgan Stanley Kyle Mikson - Canaccord Operator Good day and welcome to the PacBio First Quarter Fiscal 2022 Financial Results Conference Call. All participants will be in a listen-only mode.

Pacific Biosciences of California, Inc. (PACB) CEO Christian Henry on Q1 2022 Results - Earnings Call Transcript

MENLO PARK, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022.

PacBio Announces First Quarter 2022 Financial Results

Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: Should You Buy?

MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced an expanded research collaboration with Children's Mercy Kansas City, one of the nation's top pediatric medical systems, to use the multi-omics capabilities of PacBio's Sequel IIe system in the study of genetic disease. The research will apply direct methylation detection and Iso-Seq™ full-length RNA sequencing in their study. A better understanding of the genetic underpinnings of rare disease may ultimately help drive diagnostic yield and potentially enhance care for patients. Children's Mercy is a leader in using PacBio's genomic sequencing technology, approaching 1,000 samples sequenced since 2020.

PacBio and Children's Mercy Kansas City Expand Collaboration Taking a Multi-Omics Approach to Characterize Rare Disease

Significant enhancements to the Sequel II/IIe platform include methylation calling in native DNA, greatly accelerated sample preparation, and support for gene therapy applications Significant enhancements to the Sequel II/IIe platform include methylation calling in native DNA, greatly accelerated sample preparation, and support for gene therapy applications

PacBio transforms access to the epigenome and streamlines workflows

MENLO PARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022, at 5:00 pm Eastern Time.

PacBio to Report First Quarter 2022 Financial Results on May 4, 2022

Anyone thinking about buying shares should know them, too.

3 Things About Pacific Biosciences of California That Smart Investors Know

PacBio shares have been hit hard as investors have abandoned riskier high-multiple life sciences stocks, and weaker guidance for FY'22 certainly didn't help.

Pacific Biosciences Hit By Sentiment, But The Future Of Long-Read Sequencing Is Strong

The companies will leverage high-throughput whole genome HiFi sequencing for advanced plant biotechnology, breeding and crop protection product development The companies will leverage high-throughput whole genome HiFi sequencing for advanced plant biotechnology, breeding and crop protection product development

PacBio Enters Agricultural Industry Collaboration with Corteva Agriscience to Develop High-Throughput Plant, Pest and Microbial Sequencing

Science magazine publication details how the human genome was finally completed with the help of PacBio long-read technology Science magazine publication details how the human genome was finally completed with the help of PacBio long-read technology

HiFi Reads Enable Telomere-to-Telomere Consortium to Fill the Final Gaps in the Human Genome, Heralding a New Era of Research into Genetic Diseases and Human Biology

Company Announces New European Headquarters to Serve Growing Customer Demand in Europe, Middle East and Africa Region

PacBio Opens European Headquarters in London

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?

Why Is Pacific Biosciences (PACB) Down 13.6% Since Last Earnings Report?

PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.

PacBio (PACB) Supports SickKids With Sequencing Technology

SickKids will use HiFi Sequencing to explore potential genetic causes of a range of medical and developmental conditions SickKids will use HiFi Sequencing to explore potential genetic causes of a range of medical and developmental conditions

PacBio Supports SickKids to Investigate Use of HiFi Sequencing in Undiagnosed Genetic Conditions

Genomics Industry Veteran to Oversee Development of Robust Computational Biology Program Genomics Industry Veteran to Oversee Development of Robust Computational Biology Program

PacBio Welcomes Dr. Michael Eberle as Vice President of Computational Biology

PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.

PacBio's (PACB) Q4 Earnings Miss Estimates, Revenues Top

PacBio HiFi Sequencing Technology Will Be Used to Investigate Effect on Diagnostic Yield of Unresolved Rare Diseases in Children PacBio HiFi Sequencing Technology Will Be Used to Investigate Effect on Diagnostic Yield of Unresolved Rare Diseases in Children

KK Women's and Children's Hospital and PacBio Collaborate in Asia's First Study of Unexplained Neurodevelopmental Disorders

Pacific Biosciences of California, Inc. (PACB) CEO Christian Henry on Q4 2021 Results - Earnings Call Transcript

MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2021.

PacBio Announces Fourth Quarter and Fiscal Year 2021 Financial Results

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for

MENLO PARK, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2021 financial results on Tuesday, February 15, 2022, at 4:30 pm Eastern Time.

PacBio to Report Fourth Quarter and Full Year 2021 Financial Results on February 15, 2022

The stock price of ​Pacific Biosciences of California, a biotechnology company that develops gene sequencing systems, has seen a large fall of 38% over the last twenty-one trading days, while it is down 28% over the last week. The recent fall can be attributed to the company's preliminary Q4 results

Will Pacific Biosciences Stock Rebound After A Large 35% Fall In A Month?

PacBio's (PACB) research collaboration with Google will likely enhance its HiFi Sequencing technology to extract greater value from genomic data.

PacBio (PACB) to Leverage Google's Deep Learning Technologies

PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.

News for Pacific Biosciences of California Stock (PACB)